Singapore markets closed
Straits Times Index
3,292.27 -4.62 (-0.14%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,202.84 +30.69 (+0.38%) Bitcoin USD
59,305.00 +1,522.37 (+2.63%) CMC Crypto 200
1,284.51 +7.53 (+0.59%)
PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta - Jakarta Delayed price. Currency in IDR
Add to watchlist
At close: 03:49PM WIB
| Previous close | 1,490.00 |
| Open | 1,505.00 |
| Bid | 1,860.00 x 0 |
| Ask | 1,120.00 x 0 |
| Day's range | 1,460.00 - 1,515.00 |
| 52-week range | 1,375.00 - 2,200.00 |
| Volume | |
| Avg. volume | 36,047,552 |
| Market cap | 68.458T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 24.77 |
| EPS (TTM) | 59.75 |
| Earnings date | 02 Aug 2024 - 03 Aug 2024 |
| Forward dividend & yield | 38.00 (2.55%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | 1,747.50 |
Business WireGenexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.